New Delhi: Swiss pharma major Roche Holding AG today said it won`t pursue the secondary patent for its breast cancer drug `Herceptin` in India. "Regular reviews of our patent portfolio are a routine business practice. In this connection, Roche has come to the conclusion not to pursue Indian Patent No 205534 (the secondary patent for Trastuzumab) and the related divisional applications," a spokesperson of Roche Holding AG told PTI in an emailed response.
Taiwan:TransAsia Airways crashes during emergency landing
Basketball Asia Cup: Sikh players forced to remove turbans
Shiv Sena MPs `force` fasting Muslim to eat during Ramzan
Don`t take us for granted, NCP warns Congress